X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (39732) 39732
Book Review (13444) 13444
Publication (5283) 5283
Book Chapter (459) 459
Book / eBook (315) 315
Conference Proceeding (135) 135
Dissertation (45) 45
Reference (14) 14
Magazine Article (8) 8
Data Set (6) 6
Newsletter (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35377) 35377
humans (24663) 24663
animals (23160) 23160
mice (9876) 9876
cell biology (7712) 7712
male (7171) 7171
signal transduction (6862) 6862
female (6763) 6763
expression (6092) 6092
biochemistry & molecular biology (5694) 5694
cells, cultured (5411) 5411
oncology (5355) 5355
rats (5274) 5274
cancer (4834) 4834
proteins (4646) 4646
research (4427) 4427
inflammation (4192) 4192
gene expression (4183) 4183
pharmacology & pharmacy (4168) 4168
apoptosis (3765) 3765
physiological aspects (3760) 3760
article (3756) 3756
receptor (3562) 3562
activation (3510) 3510
immunology (3404) 3404
analysis (3327) 3327
signal transduction - drug effects (3216) 3216
neurosciences (3211) 3211
physiology (3164) 3164
receptors (3160) 3160
phosphorylation (3159) 3159
cell line, tumor (3115) 3115
cells (3091) 3091
rodents (3088) 3088
gene-expression (3061) 3061
health aspects (2933) 2933
endocrinology & metabolism (2913) 2913
kinases (2885) 2885
research article (2844) 2844
cytokines (2841) 2841
multidisciplinary sciences (2814) 2814
cell line (2687) 2687
angiogenesis (2621) 2621
medicine (2588) 2588
in-vitro (2498) 2498
cell proliferation (2473) 2473
in-vivo (2277) 2277
mice, inbred c57bl (2227) 2227
medicine, research & experimental (2187) 2187
care and treatment (2183) 2183
genetic aspects (2143) 2143
signal transduction - physiology (2100) 2100
stem cells (2087) 2087
tumors (2063) 2063
cell proliferation - drug effects (2036) 2036
disease models, animal (2034) 2034
ligands (2014) 2014
proliferation (2009) 2009
biology (1988) 1988
nf-kappa-b (1985) 1985
abridged index medicus (1961) 1961
science (1939) 1939
fibroblasts (1929) 1929
review (1911) 1911
growth (1884) 1884
development and progression (1873) 1873
rats, sprague-dawley (1829) 1829
differentiation (1819) 1819
inhibition (1784) 1784
growth factors (1756) 1756
adult (1727) 1727
metastasis (1716) 1716
mice, knockout (1714) 1714
middle aged (1702) 1702
immunohistochemistry (1673) 1673
rna, messenger - metabolism (1669) 1669
fibrosis (1668) 1668
medicine & public health (1656) 1656
dose-response relationship, drug (1636) 1636
breast cancer (1550) 1550
growth-factor (1507) 1507
biochemistry (1482) 1482
mutation (1457) 1457
up-regulation (1456) 1456
apoptosis - drug effects (1452) 1452
growth-factor receptor (1447) 1447
blotting, western (1423) 1423
endothelial growth-factor (1415) 1415
antineoplastic agents - pharmacology (1412) 1412
enzyme inhibitors - pharmacology (1404) 1404
reverse transcriptase polymerase chain reaction (1397) 1397
gene expression regulation (1376) 1376
cell differentiation (1371) 1371
biomedicine (1355) 1355
pathology (1333) 1333
models, biological (1328) 1328
genes (1285) 1285
time factors (1285) 1285
tumor-necrosis-factor (1284) 1284
oxidative stress (1283) 1283
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (236) 236
UofT at Mississauga - Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Closed Orders (10) 10
Online Resources - Online (10) 10
UTL at Downsview - May be requested (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
UofT at Scarborough - Stacks (6) 6
Chemistry (A D Allen) - Stacks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (40244) 40244
German (20) 20
Spanish (20) 20
Japanese (10) 10
French (9) 9
Chinese (2) 2
Italian (2) 2
Arabic (1) 1
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 9/2012, Volume 337, Issue 6099, pp. 1231 - 1235
The brain tumor glioblastoma multiforme (GBM) is among the most lethal forms of human cancer. Here, we report that a small subset of GBMs (3.1%; 3 of 97 tumors... 
Exons | Neurons | Genes | REPORTS | Stem cells | Aneuploidy | Chromosomes | Cells | Tumors | Daughter cells | Cancer | ANEUPLOIDY | SELECTIVE INHIBITOR | POTENT | MULTIDISCIPLINARY SCIENCES | CANCER | RECEPTOR TYROSINE KINASE | DISCOVERY | CHROMOSOMAL INSTABILITY | FAMILY | Microtubule-Associated Proteins - chemistry | Neoplasm Transplantation | Translocation, Genetic | Oncogene Proteins, Fusion - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - chemistry | Microtubule-Associated Proteins - genetics | Microtubule-Associated Proteins - metabolism | Mitosis | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Fetal Proteins - metabolism | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Brain Neoplasms - metabolism | Oncogene Proteins, Fusion - chemistry | Spindle Apparatus - metabolism | Glioblastoma - genetics | Oncogene Fusion | Glioblastoma - metabolism | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Nuclear Proteins - genetics | Chromosomal Instability | Pyrazoles - pharmacology | Protein Structure, Tertiary | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Enzyme Inhibitors - pharmacology | Brain Neoplasms - genetics | Nuclear Proteins - metabolism | Pyrimidines - pharmacology | Nuclear Proteins - chemistry | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Cell Transformation, Neoplastic | Oncogene Proteins, Fusion - genetics | Fetal Proteins - genetics | Mice | Receptor, Fibroblast Growth Factor, Type 1 - chemistry | Fetal Proteins - chemistry | Physiological aspects | Development and progression | Fibroblast growth factors | Genetic aspects | Research | Health aspects | Glioblastoma multiforme | Proteins | Kinases | Brain cancer | Genomics | Pharmaceutical sciences | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2011, Volume 54, Issue 20, pp. 7066 - 7083
Journal Article
Oncogene, ISSN 0950-9232, 06/2013, Volume 32, Issue 25, pp. 3059 - 3070
Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers, making them attractive drug targets. Here we have characterized... 
tyrosine kinase inhibitors | ERK1/2 | FGFR | PKB | acquired resistance | MULTIPLE-MYELOMA | BLADDER-CANCER | PHOSPHORYLATION | PROTEIN-KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | STOMACH-CANCER | LINES | CELL BIOLOGY | C/EBP-ALPHA | AMPLIFICATION | GENE | ONCOLOGY | GASTRIC-CANCER | GENETICS & HEREDITY | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Multiple Myeloma - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Pyrazoles - pharmacology | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Pyrimidines - pharmacology | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Receptor Protein-Tyrosine Kinases - drug effects | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Signal Transduction - drug effects | Receptors, Fibroblast Growth Factor - metabolism | Cell Line, Tumor | Mutation | Multiple Myeloma - genetics | Gene mutations | Analysis | Physiological aspects | Genetic aspects | Fibroblast growth factors | Research | Health aspects | Fibroblast growth factor receptors | Proteins | Signal transduction | Inhibitor drugs | Gene expression | Cancer | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 01/2013, Volume 73, Issue 4, pp. 1298 - 1307
Fibroblast growth factor (FGF) receptor (FGFR) substrate 2 (FRS2) is an adaptor protein that plays a critical role in FGFR signaling. FRS2 is located on... 
DEDIFFERENTIATED LIPOSARCOMA | GENE | ONCOLOGY | COPY-NUMBER | GROWTH | MDM2 | CLASSIFICATION | PLEOMORPHIC SARCOMA | EXPRESSION | CANCER | CELL-LINE | Immunohistochemistry | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Proto-Oncogene Proteins c-mdm2 - genetics | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Cyclin-Dependent Kinase 4 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Arginine - analogs & derivatives | Liposarcoma - metabolism | Neoplasm Grading | RNA Interference | Receptors, Fibroblast Growth Factor - genetics | Female | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Membrane Proteins - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Proto-Oncogene Proteins c-mdm2 - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Signal Transduction | Membrane Proteins - genetics | Liposarcoma - pathology | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Liposarcoma - genetics | Pyrimidines - pharmacology | Cyclin-Dependent Kinase 4 - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Gene Amplification | Receptors, Fibroblast Growth Factor - metabolism | Adaptor Proteins, Signal Transducing - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Phenylurea Compounds - pharmacology | Adaptor Proteins, Signal Transducing - metabolism | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Index Medicus
Journal Article
Science, ISSN 0036-8075, 12/2014, Volume 346, Issue 6216, pp. 1480 - 1486
Targeted cancer therapies have produced substantial clinical responses, but most tumors develop resistance to these drugs. Here, we describe a pharmacogenomic... 
CELL LUNG-CANCER | ALK | KINASE INHIBITION | GEFITINIB | ACTIVATION | CERITINIB | MULTIDISCIPLINARY SCIENCES | CRIZOTINIB | MUTATIONS | CHEMOTHERAPY | BYPASS MECHANISMS | Lung Neoplasms - drug therapy | Sulfones - therapeutic use | Humans | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | MAP Kinase Kinase 1 - genetics | DNA Mutational Analysis | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Tumor Cells, Cultured | Molecular Targeted Therapy - methods | Lung Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | MAP Kinase Kinase 1 - metabolism | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Patient-Specific Modeling | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Enzyme Activation - genetics | Drug Screening Assays, Antitumor | Antimitotic agents | Cancer patients | Care and treatment | Lung cancer | Dosage and administration | Genetic aspects | Antineoplastic agents | Drug therapy | Drug resistance | Methods | Cancer | Cell culture | Oncology | Pharmaceutical sciences | Index Medicus | Drugs | Mutations | Therapy | Genetics | Kinases | Patients | Tumors
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 07/2017, Volume 135, pp. 531 - 543
A series of 2-oxo-3, 4-dihydropyrimido[4,5- ]-pyrimidinyl derivatives were designed and synthesized as new irreversible inhibitors of the FGFR family. One of... 
FGFR | Irreversible inhibitor | 2-Oxo-3,4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives | CHEMISTRY, MEDICINAL | DISCOVERY | FAMILY | AZD4547 | 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives | SELECTIVE INHIBITOR | POTENT | PATHWAY | REACTIVATION | RESISTANCE | TYROSINE KINASE INHIBITOR | TARGETING FGFR | Cell Line | Protein Kinase Inhibitors - chemical synthesis | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Pyrimidines - chemical synthesis | Antineoplastic Agents - chemical synthesis | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Structure-Activity Relationship | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Molecular Structure | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Drug Screening Assays, Antitumor | Fibroblast growth factors | Enzyme inhibitors | Drug discovery | Lung cancer, Non-small cell | Derivatives (Financial instruments) | Resveratrol | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2017, Volume 60, Issue 15, pp. 6516 - 6527
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2016, Volume 27, Issue 7, pp. 1311 - 1316
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2011, Volume 104, Issue 1, pp. 75 - 82
BACKGROUND: Activating mutations of FGFR3 are frequently identified in superficial urothelial carcinoma (UC) and increased expression of FGFR1 and FGFR3 are... 
TKI-258 | urothelial carcinoma | tyrosine kinase inhibitor | FGFR3 | PD173074 | FGFR1 | GENE-MUTATIONS | BLADDER-CANCER | TYROSINE KINASE DOMAIN | PROLIFERATION | CHIR-258 | ONCOLOGY | THERAPEUTIC TARGET | T(4/14) MULTIPLE-MYELOMA | EXPRESSION | ACTIVATING MUTATIONS | CELL-CARCINOMA | Urothelium - metabolism | Apoptosis - drug effects | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Male | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Immunoenzyme Techniques | Urinary Bladder Neoplasms - prevention & control | Carcinoma, Transitional Cell - prevention & control | Quinolones - therapeutic use | Urinary Bladder Neoplasms - pathology | Phosphorylation - drug effects | Pyrroles - therapeutic use | Urinary Bladder Neoplasms - metabolism | Benzimidazoles - therapeutic use | Cells, Cultured | Carcinoma, Transitional Cell - metabolism | Mutation - genetics | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Blotting, Western | Xenograft Model Antitumor Assays | Animals | Carcinoma, Transitional Cell - pathology | Pyrimidines - therapeutic use | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Cell Cycle - drug effects | In Vitro Techniques | Urothelium - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus | Translational Therapeutics
Journal Article
Biochemical Journal, ISSN 0264-6021, 09/2012, Volume 446, Issue 2, pp. 235 - 241
PRMT5 (protein arginine methyltransferase 5) is an enzyme that catalyses transfer of methyl groups from S-adenosyl methionine to the arginine residues of... 
Proliferation | Fibroblast growth factor receptor (FGFR) | Protein arginine methyltransferase 5 (PRMT5) | Lung cancer | SM PROTEINS | PRMT5 | METHYLATION | COMPLEX | fibroblast growth factor receptor (FGFR) | proliferation | FGF RECEPTORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | TRANSCRIPTION | IDENTIFICATION | lung cancer | protein arginine methyltransferase 5 (PRMT5) | GENE-EXPRESSION | TUMOR-SUPPRESSOR | RB FAMILY | Neoplasm Transplantation | Adenocarcinoma - pathology | Cell Proliferation | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Protein-Arginine N-Methyltransferases - antagonists & inhibitors | Small Cell Lung Carcinoma - enzymology | Lung Neoplasms - pathology | Neoplasm Proteins - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Gene Expression Profiling | Neoplasm Proteins - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Lung - enzymology | Small Cell Lung Carcinoma - metabolism | Adenocarcinoma - metabolism | Lung - metabolism | Protein-Arginine N-Methyltransferases - genetics | Neoplasm Proteins - genetics | Mutant Proteins - antagonists & inhibitors | Recombinant Proteins - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Carcinoma, Squamous Cell - enzymology | Lung - pathology | Recombinant Proteins - antagonists & inhibitors | Lung Neoplasms - enzymology | Signal Transduction | Adenocarcinoma - enzymology | Gene Silencing | Mutant Proteins - metabolism | Tumor Burden | Protein-Arginine N-Methyltransferases - metabolism | Small Cell Lung Carcinoma - pathology | Animals | Mice, Nude | Cell Line, Tumor | Mice | RNA, Small Interfering | Index Medicus | FGFR | protein arginine methyltransferase
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1216 - 1229
Overexpression of FGF receptor 3 (FGFR3) is implicated in the development of t(4;14)-positive multiple myeloma. While FGFR3 is frequently overexpressed and/or... 
MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | THANATOPHORIC DYSPLASIA | STRUCTURAL BASIS | THERAPEUTIC TARGET | GROWTH-FACTOR RECEPTOR-3 | GENE-EXPRESSION | MONOCLONAL-ANTIBODY | TUMOR-CELLS | CANCER | ACTIVATING MUTATIONS | Humans | Protein Conformation - drug effects | Antibody-Dependent Cell Cytotoxicity - immunology | Antibodies, Monoclonal - therapeutic use | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Cell Line, Tumor - drug effects | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Epitopes - immunology | Fibroblast Growth Factors - metabolism | Multiple Myeloma - therapy | RNA Interference | Protein Binding - drug effects | Urinary Bladder Neoplasms - pathology | Female | Membrane Proteins - metabolism | Phosphorylation - drug effects | Urinary Bladder Neoplasms - metabolism | Antibodies, Monoclonal - immunology | Antibodies, Monoclonal - pharmacology | Models, Molecular | Mice, SCID | Xenograft Model Antitumor Assays | Multiple Myeloma - pathology | Animals | Signal Transduction - drug effects | Antigen-Antibody Complex - chemistry | Mice, Nude | Receptor, Fibroblast Growth Factor, Type 3 - immunology | Urinary Bladder Neoplasms - therapy | Cell Proliferation - drug effects | Epitopes - chemistry | Mice | Adaptor Proteins, Signal Transducing - metabolism | Multiple Myeloma - genetics | Mitogen-Activated Protein Kinases - metabolism | Translocation, Genetic - genetics | Embryonic development | Multiple myeloma | Physiological aspects | Genetic aspects | Research | Diagnosis | Bladder cancer | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
13.